Received May 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 3 | y018154 | — |
No other AE; patient who received a 3rd dose of MMR-II yesterday (13MAY2025) and should've only received two doses.; This spontaneous report has been received from a consumer or other non-health professional regarding to a 11-year-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, and previous drug reactions or allergies were not reported. On 17-APR-2025, the patient received the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), then on 13-MAY-2025, then on an unspecified date in 2025, she received the second dose, both at a dose of 0.5 milliliter as prophylaxis (vaccination scheme, route of administration, anatomical site of injection, lot number and expiration date were not reported). On 13-MAY-2025, the patient received the third dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (Extra dose administered) at a dose of 0.5 ml, as prophylaxis, lot number y018154 which had been verified to be an invalid number (vaccination scheme, route of administration, and anatomical site of injection, were not reported). No additional adverse events were reported in the patient.
Sterile diluent